Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy

被引：4

作者：

Lee, Bo-Hee ^{[1
]}

Shin, Seung Hwan ^{[2
]}

Min, Chang-Ki ^{[2
]}

Yhim, Ho-Young ^{[3
]}

Kwak, Jae-Yong ^{[3
]}

Kim, Jeong-A ^{[1
]}

机构：

[1] Catholic Univ Korea, Dept Hematol, St Vincents Hosp, Coll Med, Seoul 137701, South Korea

[2] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Div Hematol,Dept Internal Med, Seoul 137701, South Korea

[3] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju, South Korea

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2013年 / 97卷 / 05期

关键词：

Multiple myeloma; Bortezomib; Induction therapy; Transplantation; Complete response; PLUS DEXAMETHASONE; BORTEZOMIB; THALIDOMIDE; SUPERIOR;

D O I：

10.1007/s12185-013-1311-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To examine the role of high-dose melphalan therapy with autologous stem cell transplantation (HDM/ASCT) in the final outcomes of multiple myeloma (MM) patients receiving bortezomib-containing induction therapy (IT), we analyzed relationships between quality of response after IT including bortezomib or HDM/ASCT and survival. In total, 92 MM patients who received IT with bortezomib followed by HDM/ASCT were enrolled. The median follow-up was 28.0 months. Three-year progression-free survival (PFS) and overall survival (OS) were 41.1 and 72.0 %, respectively. A complete response (CR) after HDM/ASCT was a strong prognostic factor for PFS and OS (p = 0.002 and 0.001, respectively). Additionally, out of 67 patients who failed to achieve CR after IT, 36 (53.7 %) patients achieved CR after HDM/ASCT. PFS and OS in patients with CR after additional HDM/ASCT were similar to those in patients who had already achieved CR after IT. However, achievement of at least very good partial response following IT with bortezomib failed to improve PFS and OS (p = 0.35 and 0.11, respectively). Thus, we conclude that post-HDM/ASCT CR is the best prognostic factor for both PFS and OS regardless of response to bortezomib. Therefore, HDM/ASCT remains an important therapy in MM patients even after introduction of bortezomib IT.

引用

页码：634 / 639

页数：6

共 17 条

[1] Impact of response to thalidomide-, lenalidomide- or bortezomib-containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation [J].

Awan, F. T. ;

Osman, S. ;

Kochuparambil, S. T. ;

Gibson, L. ;

Remick, S. C. ;

Abraham, J. ;

Craig, M. ;

Jillella, A. ;

Hamadani, M. .

BONE MARROW TRANSPLANTATION, 2012, 47 (01) :146-148

[2] Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study [J].

Cavo, Michele ;

Tacchetti, Paola ;

Patriarca, Francesca ;

Petrucci, Maria Teresa ;

Pantani, Lucia ;

Galli, Monica ;

Di Raimondo, Francesco ;

Crippa, Claudia ;

Zamagni, Elena ;

Palumbo, Antonio ;

Offidani, Massimo ;

Corradini, Paolo ;

Narni, Franco ;

Spadano, Antonio ;

Pescosta, Norbert ;

Deliliers, Giorgio Lambertenghi ;

Ledda, Antonio ;

Cellini, Claudia ;

Caravita, Tommaso ;

Tosi, Patrizia ;

Baccarani, Michele .

LANCET, 2010, 376 (9758) :2075-2085

[3] International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders [J].

Dispenzieri, A. ;

Kyle, R. ;

Merlini, G. ;

Miguel, J. S. ;

Ludwig, H. ;

Hajek, R. ;

Palumbo, A. ;

Jagannath, S. ;

Blade, J. ;

Lonial, S. ;

Dimopoulos, M. ;

Comenzo, R. ;

Einsele, H. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Harousseau, J. L. ;

Attal, M. ;

Tosi, P. ;

Sonneveld, P. ;

Boccadoro, M. ;

Morgan, G. ;

Richardson, P. ;

Sezer, O. ;

Mateos, M. V. ;

Cavo, M. ;

Joshua, D. ;

Turesson, I. ;

Chen, W. ;

Shimizu, K. ;

Powles, R. ;

Rajkumar, S. V. ;

Durie, B. G. M. .

LEUKEMIA, 2009, 23 (02) :215-224

[4] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[5] International Myeloma Working Group molecular classification of multiple myeloma: spotlight review [J].

Fonseca, R. ;

Bergsagel, P. L. ;

Drach, J. ;

Shaughnessy, J. ;

Gutierrez, N. ;

Stewart, A. K. ;

Morgan, G. ;

Van Ness, B. ;

Chesi, M. ;

Minvielle, S. ;

Neri, A. ;

Barlogie, B. ;

Kuehl, W. M. ;

Liebisch, P. ;

Davies, F. ;

Chen-Kiang, S. ;

Durie, B. G. M. ;

Carrasco, R. ;

Sezer, Orhan ;

Reiman, Tony ;

Pilarski, Linda ;

Avet-Loiseau, H. .

LEUKEMIA, 2009, 23 (12) :2210-2221

[6] Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial [J].

Harousseau, Jean-Luc ;

Attal, Michel ;

Avet-Loiseau, Herve ;

Marit, Gerald ;

Caillot, Denis ;

Mohty, Mohamad ;

Lenain, Pascal ;

Hulin, Cyrille ;

Facon, Thierry ;

Casassus, Philippe ;

Michallet, Mauricette ;

Maisonneuve, Herve ;

Benboubker, Lotfi ;

Maloisel, Frederic ;

Petillon, Marie-Odile ;

Webb, Iain ;

Mathiot, Claire ;

Moreau, Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4621-4629

[7] The role of complete response in multiple myeloma [J].

Harousseau, Jean-Luc ;

Attal, Michel ;

Avet-Loiseau, Herve .

BLOOD, 2009, 114 (15) :3139-3146

[8] Update on risk stratification and treatment of newly diagnosed multiple myeloma [J].

Kapoor, Prashant ;

Rajkumar, S. Vincent .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 94 (04) :310-320

[9] DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma [J].

Kropff, Martin ;

Liebisch, Peter ;

Knop, Stefan ;

Weisel, Katja ;

Wand, Hannes ;

Gann, Claudia-Nanette ;

Berdel, Wolfgang E. ;

Einsele, Herrmann .

ANNALS OF HEMATOLOGY, 2009, 88 (11) :1125-1130

[10] Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance [J].

Nair, Bijay ;

van Rhee, Frits ;

Shaughnessy, John D., Jr. ;

Anaissie, Elias ;

Szymonifka, Jackie ;

Hoering, Antje ;

Alsayed, Yazan ;

Waheed, Sarah ;

Crowley, John ;

Barlogie, Bart .

BLOOD, 2010, 115 (21) :4168-4173

← 1 2 →